Clinical and Pathological Response to Primary Chemotherapy in Patients with Locally Advanced Breast Cancer Grouped According to Hormonal Receptors, Her2 Status, Grading and Ki-67 Proliferation Index
Objectives: Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67 proliferation index before and after neoadjuvant c...
Saved in:
Published in | Anticancer research Vol. 29; no. 5; pp. 1621 - 1625 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Attiki
International Institute of Anticancer Research
01.05.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objectives: Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have
considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67
proliferation index before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). Patients
and Methods: Fifty-five patients received neoadjuvant chemotherapy for LABC. The incidence of clinical and pathological responses
was assessed with respect to basal clinical stage, absent/low vs. high ER and PgR status, low vs. high proliferation index,
grading and Her2 overexpression. Results: Overall, 30 patients (54%) underwent downstaging of their primary tumor; pathological
complete remission was observed in only one patient with Her2 positive breast tumor. Patients with pre-treatment Ki-67 >20%,
Her2 overexpression, T2b/T3 vs. T4 clinical stage achieved higher response rate. Conclusion: The future of neoadjuvant therapy
lies in tailoring treatment to individual patients by identifying response predictors; although the number of patients reported
is small, this study confirms that clinical stage at diagnosis, Ki-67 reduction and Her2 overexpression are predictive of
tumor response to neoadjuvant regimens. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0250-7005 1791-7530 |